Futura Medical plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Alexander James Hanbury Duggan
- Full Time Employees
- 14
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Surrey Technology Centre Guildford SU United Kingdom GU2 7YG
- IPO Date
- Jul 10, 2006
- Website
- futuramedical.com
- Similar Companies
- Business
- Futura Medical plc develops and commercializes innovative sexual health products focused on topical gel formulations for over-the-counter use. The company offers Eroxon, a clinically proven, fast-acting topical gel for erectile dysfunction that works within 10 minutes and is available without prescription; Eroxon Intense, a stronger-sensation extension in development with home user study results expected in Q1 2026 and potential regulatory approval in H1 2026; and WSD4000, an early-stage topical treatment for impaired sexual response in women with early feasibility study results anticipated in H1 2026. Products target consumers seeking non-prescription alternatives to traditional treatments, with distribution through partners including Haleon in the United States, Cooper Consumer Health in Europe and the United Kingdom, Labatec in the Middle East, and M8 Pharmaceuticals in Mexico; operations span over 15 countries in Europe, the Middle East, North America, and Latin America. Founded in 2001 and headquartered at Surrey Technology Centre in Guildford, United Kingdom, Futura Medical employs a partner-led commercialization strategy to leverage marketing expertise in major markets. In November 2025, the company raises gross proceeds of 2.75 million pounds through a placing and subscription of 275 million new shares at 1 pence each to fund development of Eroxon Intense and WSD4000 amid slower-than-expected Eroxon sales; appoints Alex Duggan as permanent chief executive officer; and pursues US patent milestone payment of US$2.5 million from Haleon in H1 2026 alongside commercial reviews with partners.
Company News
Futura Medical revises sale timetable as finance director steps down
Futura Medical plans 2027 Eroxon Intense launch after positive test
Futura Medical upsizes retail offer after strong investor demand
Futura Medical upsizes retail offer after strong investor demand
Dow closes with strong gains as rate fears take a back seat
Bitcoin price recovery narrows odds on higher 2026 targets, prediction market data shows
Futura Medical launches formal sale process alongside £1.6m placing
Futura Medical advances Eroxon pipeline as it reshapes US commercial strategy
Futura Medical gets greenlight for stronger product "Eroxon Intense"
Futura Medical gets greenlight for stronger product "Eroxon Intense"
Futura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMI
Futura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMI
Exxon Mobil updates Q2 earnings considerations, cites impacts across key businesses
Futura to appeal European patent decision
Samsung plunges despite earnings beat, sparking fresh AI stock jitters for Nasdaq names
FTSE 100 Live: Stocks slide despite airlines and defence gains, Microsoft slashes jobs
FTSE 100 Live: Stocks slide despite airlines and defence gains, US tech futures rise
FTSE 100 Live: London index at 10-week high as Sainsbury's, miners and banks climb
Nasdaq leads Wall Street higher at the open as uneasy Iran truce holds
Futura swaps Haleon for Market Performance Group to drive US Eroxon sales - UPDATE